These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10968405)

  • 41. Tissue schizontocidal effect of trifluoroacetyl primaquine in Plasmodium yoelii infected mice and Plasmodium cynomolgi infected monkeys.
    Shao BR; Ye XY
    Southeast Asian J Trop Med Public Health; 1991 Mar; 22(1):81-3. PubMed ID: 1948265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experimental studies on combinations of pyronaridine/primaquine versus chloroquine/primaquine.
    Shao BR; Zhan CQ; Chen KY; Ye XY; Lin BY; Ha SH; Zhang JX
    Chin Med J (Engl); 1990 Dec; 103(12):1024-6. PubMed ID: 2127247
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The chemotherapy of rodent malaria. LVIII. Drug combinations to impede the selection of drug resistance, Part. 2: The new generation--artemisinin or artesunate with long-acting blood schizontocides.
    Peters W; Robinson BL
    Ann Trop Med Parasitol; 2000 Jan; 94(1):23-35. PubMed ID: 10723521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel bis- and tris-1,2,4-trioxanes: synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in Swiss mice.
    Singh C; Verma VP; Naikade NK; Singh AS; Hassam M; Puri SK
    J Med Chem; 2008 Dec; 51(23):7581-92. PubMed ID: 19006381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of pyronaridine against African strains of Plasmodium falciparum.
    Basco LK; Le Bras J
    Ann Trop Med Parasitol; 1992 Oct; 86(5):447-54. PubMed ID: 1288425
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of Ayush-64 for blood schizontocidal activity against rodent and simian malaria parasites.
    Kazim M; Puri SK; Dutta GP; Narasimham MV
    Indian J Malariol; 1991 Dec; 28(4):255-8. PubMed ID: 1824361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of poly ICLC treatment on hepatic oxidative stress and antioxidant defense indices in Plasmodium yoelii nigeriensis infected mice.
    Siddiqi NJ; Alhomida AS; Maheshwari RK; Pandey VC
    In Vivo; 2001; 15(1):77-80. PubMed ID: 11286134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The chemotherapy of rodent malaria. LIV. Combinations of 'Fenozan B07' (Fenozan-50F), a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane, with other drugs against drug-sensitive and drug-resistant parasites.
    Fleck SL; Robinson BL; Peters W
    Ann Trop Med Parasitol; 1997 Jan; 91(1):33-9. PubMed ID: 9093427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis of new 6-alkylvinyl/arylalkylvinyl substituted 1,2,4-trioxanes active against multidrug-resistant malaria in mice.
    Singh C; Gupta N; Puri SK
    Bioorg Med Chem; 2004 Nov; 12(21):5553-62. PubMed ID: 15465332
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative evaluation of blood schizontocidal activity of quinine and quinidine against drug resistant rodent malaria.
    Kazim M; Puri SK; Dutta GP
    J Commun Dis; 1991 Dec; 23(4):254-6. PubMed ID: 1842807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of pyronaridine against field isolates and reference clones of Plasmodium falciparum.
    Childs GE; Häusler B; Milhous W; Chen C; Wimonwattrawatee T; Pooyindee N; Boudreau EF
    Am J Trop Med Hyg; 1988 Jan; 38(1):24-9. PubMed ID: 3277460
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 6-(4'-Aryloxy-phenyl)vinyl-1,2,4-trioxanes: a new series of orally active peroxides effective against multidrug-resistant Plasmodium yoelii in Swiss mice.
    Singh C; Verma VP; Naikade NK; Singh AS; Hassam M; Puri SK
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4459-63. PubMed ID: 20598529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pyronaridine: yet another promising antimalarial substance from China.
    Ceylon Med J; 1996 Sep; 41(3):123-4. PubMed ID: 8917979
    [No Abstract]   [Full Text] [Related]  

  • 54. The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo.
    Chen M; Brøgger Christensen S; Zhai L; Rasmussen MH; Theander TG; Frøkjaer S; Steffansen B; Davidsen J; Kharazmi A
    J Infect Dis; 1997 Nov; 176(5):1327-33. PubMed ID: 9359735
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of pyronaridine on ultrastructure of erythrocytic forms of Plasmodium berghei in mice].
    Wu LJ
    Zhongguo Yao Li Xue Bao; 1985 Dec; 6(4):280-3. PubMed ID: 2945375
    [No Abstract]   [Full Text] [Related]  

  • 56. A 5-year surveillance of sensitivity in vivo of Plasmodium falciparum to pyronaridine/sulfadoxine/pyrimethamine in Diaoluo area, Hainan Province.
    Shao BR; Huang ZS; Shi XH; Meng F
    Southeast Asian J Trop Med Public Health; 1991 Mar; 22(1):65-7. PubMed ID: 1948261
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Orally active 1,2,4-trioxepanes: synthesis and antimalarial activity of a series of 7-arylvinyl-1,2,4-trioxepanes against multidrug-resistant Plasmodium yoelii in Swiss mice.
    Singh C; Pandey S; Sharma M; Puri SK
    Bioorg Med Chem; 2008 Feb; 16(4):1816-21. PubMed ID: 18054238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pyronaridine--a new antimalarial drug].
    Shao BR
    Zhonghua Nei Ke Za Zhi; 1985 Nov; 24(11):691-2. PubMed ID: 3914406
    [No Abstract]   [Full Text] [Related]  

  • 59. In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum.
    Ringwald P; Eboumbou EC; Bickii J; Basco LK
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1525-7. PubMed ID: 10348789
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.
    Sagara I; Beavogui AH; Zongo I; Soulama I; Borghini-Fuhrer I; Fofana B; Camara D; Somé AF; Coulibaly AS; Traore OB; Dara N; Kabore MJ; Thera I; Compaore YD; Sylla MM; Nikiema F; Diallo MS; Dicko A; Gil JP; Borrmann S; Duparc S; Miller RM; Doumbo OK; Shin J; Bjorkman A; Ouedraogo JB; Sirima SB; Djimdé AA
    Lancet Infect Dis; 2016 Feb; 16(2):189-98. PubMed ID: 26601738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.